

Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Renal Cell Carcinoma (Faculty Presentations)**THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. Data recently presented at the 2021 Genitourinary Cancers Symposium from the Phase III CheckMate 9ER trial evaluating nivolumab with cabozantinib versus sunitinib as first-line therapy for patients with advanced renal cell carcinoma (RCC) demonstrated which of the following outcomes with the combination regimen?**
 - Improvement in objective response rate, progression-free survival (PFS) and overall survival (OS)
 - No improvement in objective response rate, PFS or OS
- 2. Recent data from the Phase III CLEAR trial evaluating lenvatinib/pembrolizumab, lenvatinib/everolimus or sunitinib as first-line therapy for patients with advanced RCC demonstrated which of the following results in comparison to the sunitinib arm?**
 - A statistically significant OS benefit with both lenvatinib/pembrolizumab and lenvatinib/everolimus
 - A statistically significant OS benefit with lenvatinib/pembrolizumab only
- 3. Which of the following drug types best describes the mechanism of action of belzutifan (MK-6482)?**
 - VEGFR tyrosine kinase inhibitor (TKI)
 - Hypoxia-inducible factor-2 alpha (HIF-2 α) inhibitor
 - Immune checkpoint inhibitor
- 4. The Phase III TIVO-3 trial comparing tivozanib to sorafenib for patients with advanced RCC who had experienced disease progression on or after 2 prior regimens, including a VEGFR TKI, demonstrated which of the following outcomes?**
 - Superior PFS with tivozanib
 - Similar PFS with tivozanib and sorafenib
 - Superior PFS with sorafenib